Synchronous and Metachronous Metastatic Breast Cancer, with Different Histology and Opposite Immunophenotype, Treated with Combination of Chemotherapy, Anti-Her2, and Endocrine Therapy: A Case Report

Giacomina Megaro; Luigi Rossi; Serena Ceddia; Marsela Sinjari; Adele Mannino; Elisa Gozzi; Antonella Cosimati; Martina Brandi; Victoria Bitca; Ilaria Toscani; Giuseppe Cimino; Silverio Tomao

doi:10.1159/000507433

Synchronous and Metachronous Metastatic Breast Cancer, with Different Histology and Opposite Immunophenotype, Treated with Combination of Chemotherapy, Anti-Her2, and Endocrine Therapy: A Case Report

Case Rep Oncol. 2020 May 13;13(2):544-549. doi: 10.1159/000507433. eCollection 2020 May-Aug.

Authors

Affiliations

¹ Department of Paediatric Haematology and Oncology, Ospedale Bambin Gesù, Rome, Italy.
² UOC of Oncology - ASL Latina - Distretto 1, University of Rome "Sapienza", Aprilia, Italy.
³ Medical Oncology Ospedale G. da Saliceto, Piacenza, Italy.
⁴ Department of Cellular Biotechnology and Haematology, University of Rome "Sapienza", Rome, Italy.
⁵ Medical Oncology Unit A Policlinico Umberto I, University of Rome "Sapienza", Rome, Italy.

Abstract

In the case of our patient, the synergic action of endocrine therapy and chemotherapy plus dual anti-HER2 combination allowed a complete disease control. Therapy should be scheduled by considering the two cancers as individual entities. The approach to breast cancer is changing from being considered a singular disease to a multiform one, according to current research focused on biological markers such as HER2, ERs, and PRs, with important implications in clinical, prognostic, and therapeutic features.

Keywords: Bilateral breast cancer; Case report; Contralateral breast; Infiltrating ductal carcinoma; Infiltrating lobular carcinoma; Metachronous cancer; Synchronous cancer.

Publication types

Case Reports